Actinogen Medical (ACW) 2024年年度报告「ASX」.pdf

1、2024Annual reportWho we are 1Highlights 2The Xanamem pipeline 3XanaCIDD depression trial results 4Xanamem progressing to advanced clinical trial phase 6Clinical trials program overview 7Chairs letter 8Chief Executive Officers letter 10Vision and strategy 12Operating&financial review 14Board of direc

2、tors 22Executive leadership team 24Directors report 26Remuneration report(Audited)29Auditors independence declaration 42Financial report 43Notes to the financial statements 48Directors declaration 68Independent auditors report 69Shareholder information 73 Corporate directory 75DisclaimerThis annual

3、report may contain certain forward-looking statements that are not historical facts;are based on subjective estimates,assumptions and qualifications;and relate to circumstances and events that have not taken place and may not take place.Such forward looking statements should be considered“at-risk st

4、atements”-not to be relied upon as they are subject to known and unknown risks,uncertainties and other factors(such as significant business,economic and competitive uncertainties/contingencies and regulatory and clinical development risks,future outcomes and uncertainties)that may lead to actual res

5、ults being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements.You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.Actinogen Medical does not undertake a

6、ny obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof,or to reflect the occurrence of or non-occurrence of any future events.Past performance is not a reliable indicator of future performance.Actinogen Medical does not make any guarant